News | March 25, 2019
Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately...
Every industry has its own vocabulary and script. In medicine, especially in dermatology training, the fundamentals start with vocabulary. Morphology, pathology, and physical exam findings all have unique descriptions and words that take...
Dermatologists and practice staff daily must surmount numerous administrative hurdles to help ensure that their patients receive recommended care and treatment and that the patient’s insurance plan covers what’s been prescribed....
Diane Berson, MD talks to Joel L. Cohen, MD about current and investigational hormone inhibitors for the treatment of acne. She discusses the safety and efficacy of spironolactone for adult female patients, especially those who suffer from cyclical acne. She also discusses a new topical androgen receptor inhibitor that is currently being investigated for treating acne by reducing sebum production.
Diane Berson, MD talks to Joel L. Cohen, MD about current and investigational hormone inhibitors for the treatment of acne. She discusses the safety...
This is dedicated to our friends in pharma…and you know who you are.
Neal Bhatia, MD, FAAD
Complaints and concerns abound, but remedies are slow in coming.
Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Program
The evidence is in: Mental well-being influences the skin.
Helen Taylor, PhD
After the acute treatment phase, experts urge a long-view on management.
Most patients will always remain acne-prone, but the right interventions can keep their skin healthy.
Nancy J. Samolitis, MD, FAAD